Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Supervised injectable hydromorphone plus oral opioid agonist treatment for opioid use disorder
ACTRN12621001729819Phase 4Completed
- Sponsor
- St Vincent's Hospital Sydney
- Start
- Apr 2022
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of hydromorphone, methadone and buprenorphine in opioid use disorder (OUD), sponsored by St Vincent's Hospital Sydney. Primary endpoints: Feasibility by recruitment, Feasibility by retention on treatment and 2 more. Started Apr 2022; status: completed.
02
Drugs
hydromorphonemethadonebuprenorphine
03
Conditions
opioid use disorder (OUD)
Beyond the preview
Go deeper on ACTRN12621001729819.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ACTRN12621001729819.